



[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)

Date: March 5, 2020

Time: 8:00 AM to 5:00 PM

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health
Neuroscience Center Building
6001 Executive Blvd
Rockville, MD 20852

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
National Institute on Drug Abuse
National Institutes of Health
6001 Executive Blvd. Room 4235 MSC 9550
Bethesda, MD 20892-9550
301-827-5819
gm145a@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: February 14, 2020.

Tyeshia M. Roberson, Program Analyst,
Office of Federal Advisory Committee Policy.
[FR Doc. 2020-03444 Filed: 2/20/2020 8:45 am; Publication Date: 2/21/2020]